Thermo Fisher Scientific PDCD1LG2 Monoclonal Antibody (3C9)

Applications and Tested Dilution

Product Specifications

Product Specific Information

Protein sequence:

ALFTVTVPKE LYIIEHGSNV TLECNFDTGS HVNLGAITAS LQKVENDTSP HRERATLLEE QLPLGKASFH IPQVQVRDEG QYQCIIIYGV AWDYKYLTLK VKA

Target Information

Programmed death-ligand 2 (PD-L2), also known as B7-DC, is a member of the B7 ligand family within the immunoglobulin superfamily. Along with PD-L1, it acts as a ligand for PD-1. PD-L2 is primarily expressed in dendritic cells but can be induced on various immune and non-immune cells depending on the microenvironment. Expression is upregulated by Th2 cytokine IL-4 and, to a lesser degree, by Th1 cytokines TNF-α and IFN-γ.

Although PD-L2 is generally expressed at lower levels than PD-L1, it shows a 2–6 times higher affinity for PD-1. PD-1 and its ligands serve as inhibitory immune checkpoint molecules, providing negative feedback to regulate immune homeostasis. Ligation of PD-L2 or PD-L1 inhibits T-cell activation, proliferation, and cytokine secretion (e.g., IFN-γ, IL-10), thereby dampening immune responses. Interestingly, PD-L2 can also stimulate T-cell proliferation and cytokine production even in PD-1-deficient T cells, suggesting additional receptors.

Recent studies have identified repulsive guidance molecule b (RGMb) as a second receptor for PD-L2. RGMb, initially known as a receptor for bone morphogenetic proteins (BMPs), is expressed in the central nervous system and macrophages. Interaction between PD-L2 and RGMb regulates respiratory tolerance development in the lung through BMP and/or neogenin signaling pathways.

The naturally occurring human PD-L2 monomer consists of:

• 201-amino-acid extracellular domain
• 21-amino-acid transmembrane domain
• 32-amino-acid cytoplasmic domain

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.